# Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

> **NCT06291376** · PHASE3 · RECRUITING · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 510 (estimated)

## Conditions studied

- Immunoglobulin A Nephropathy
- IgAN

## Interventions

- **DRUG:** Ravulizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06291376
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-29
- **Primary completion:** 2026-01-05
- **Final completion:** 2030-07-19
- **Target enrollment:** 510 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06291376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06291376, "Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06291376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*